Abstract
Background Recent researches reported the impact of the coronavirus disease 2019 (COVID – 19) pandemic on the clinical practice of specific type cancers. The aim of this study was to reveal the impact of the COVID-19 outbreak on the clinical practice of various cancers.
Methods We included hospitalized patients aged 18 years or older diagnosed between July 2018 and June 2020 with one of the top 12 most common cancers in Japan (colon/rectum, lung, gastric, breast, bladder & urinary tract, pancreas, non-Hodgkin lymphoma, liver, prostate, esophagus, uterus, and gallbladder & biliary tract) using Diagnostic Procedure Combination data, an administrative database in Japan. The intervention was defined April 2020 based on a declaration of emergency from Japanese government. The change volume of number of monthly admissions with each cancer was tested by interrupted time series (ITS) analysis, and monthly cases with radical surgery or chemotherapy for each cancer were descripted.
Results 403,344 cases were included during the study period. The most common cancer was colon/rectum (20.5%), followed by lung (17.5%). In almost cancer cases, the number of admissions decreased in May 2020. In particular, colorectal, lung, gastric, breast, uterine, or esophageal cancer cases decreased by over 10%. The number of admissions with surgery or chemotherapy decreased in colorectal, lung, gastric, breast, uterine, or esophageal cancer. ITS analysis indicated that cases with gastric or esophageal cancer were affected more than other type of cancer.
Conclusions The COVID-19 outbreak has a negative impact on the number of admission cases with cancer; the magnitude of impact varied by cancer diagnosis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The present study was supported by JSPS KAKENHI Grant numbers JP19H01075 from the Japan Society for the Promotion of Science, Health Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare, Japan, Grant Numbers 20HA2003 and by GAP Fund Program of Kyoto University, Type B (2020) to Yuichi Imanaka.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The present study was approved by the ethics committee of Kyoto University (approval number: R0135), and we did not require informed consent because of the use of anonymized data, in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects, as stipulated by the Japanese Government.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
E-mail Hisashi Itoshima: itoshima.hisashi.48a{at}st.kyoto-u.ac.jp, Yuka Asami: asami.yuka.73m{at}st.kyoto-u.ac.jp, Jung-ho Shin: shin.jungho.76v{at}st.kyoto-u.ac.jp, Daisuke Takada: takada.daisuke.76a{at}st.kyoto-u.ac.jp, Tetsuji Morishita: morishita.tetsuji.42z{at}st.kyoto-u.ac.jp, Seiko Bun: bun.seiko.58w{at}st.kyoto-u.ac.jp, Takuya Okuno: okuno.takuya.54e{at}st.kyoto-u.ac.jp, Susumu Kunisawa: kunisawa.susumu.2v{at}kyoto-u.ac.jp, Yuichi Imanaka: imanaka-y{at}umin.net
Section on Acknowledgments updated to add the information of founders.
Data Availability
The datasets generated during and/or analyzed during the present study are available from the corresponding author on reasonable request.
